Gautret et al.[8]
|
Multicenter, open-label, non-randomized CT, France
|
HBP: NR
Diabetes: NR
Obesity: NR
|
Asymptomatic: 16.7
URTI symptoms: 61.1
|
4
|
500 day 1, 250 OD days 2-5
|
|
PCR negative day 6 (P=0.001)
|
|
|
|
|
|
|
HCQ: 20 |
57.1 % |
|
|
|
|
|
|
HCQ + AZT: 6 |
100 % |
|
|
|
|
|
|
SOC: 16 |
12.5 % |
Gautret et al.[72]
|
Single center, retrospective, observational study, France
|
HBP: 16
Diabetes: 11
Obesity: 5
|
Asymptomatic: 5.0
URTI symptoms: 41.2
NEWS low (0-4): 92
|
5
|
500 day 1, 250 OD days 2-5
|
HCQ + AZT: 80
|
Day 7:
81 % clinical cure
3.8 % transferred to ICU
83 % PCR negative
|
Million et al.[73]
|
Single center, retrospective, observational study, France
|
HBP: 14
Diabetes: 7
Obesity: 6
|
NEWS low (0-4): 95
|
6
|
500 day 1, 250 OD days 2-5
|
HQC + AZT: 1,061
|
Day 7:
91.7 % clinical and virological cure
0.9 % transferred to ICU
0.8 % died
|
Molina et al.[74]
|
Single center, retrospective, observational study, France
|
HBP: NR
Diabetes: NR
Obesity: 18
Cancer: 46
|
NR
|
NR
|
500 day 1, 250 OD days 2-5
|
HCQ + AZT: 11
|
Day 5:
9 % died
18.2 % transferred to ICU
Day 6:
80 % PCR positive
|
Mahevas et al.[75]
|
Multicenter, retrospective, propensity-score matched observational
study, France
|
HBP: 51
Diabetes: 9
Obesity: 26
|
>50 % extend on CT: 33
|
7
|
500 day 1, 250 OD days 2-5
|
|
21-day mortality % and HR:
|
|
|
|
|
|
|
HCQ: 84
HCQ + AZT: 15
|
HCQ: 11 %, 1.2 (95 % CI 0.4-3.3)
|
|
|
|
|
|
|
Control: 89
AZT: 26 (29.2 %)
|
Control: 9 %. Reference
|
Magagnoli et al.[76]
|
National retrospective, propensity-score matched observational study,
USA
|
HBP: NR
Diabetes: 67.7
BMI: 29.8
Charlson: 2.3
|
Albumin < 2.8 g/dL: 17.6
Heart rate >100 lpm: 15.5
|
NR
|
NR
|
|
In-hospital mortality % and aHR:
|
|
|
|
|
|
|
HCQ: 198 |
19.2, 1.83 (95 % CI 1.16-2.89) |
|
|
|
|
|
|
HCQ + AZT: 214 |
22.9, 1.31 (95 % CI
0.80-2.15) |
|
|
|
|
|
|
No HCQ: 395
AZT: 91 (23.0 %)
|
9.4 %. Reference
|
Geleris et al.[77]
|
Single center, retrospective, propensity-score matched observational
study, USA
|
HBP: 52
Diabetes: 36
Obesity: 41
|
Median values:
Pao2/Fio2: 248 mmHg
Oxygen saturation: 94 %
Heart rate: 98 bpm
Ferritin: 665 ng/ml
|
NR
|
500 day 1, 250 OD days 2-5
|
HCQ: 811
HCQ + AZT: 486 (59.9 %)
|
Time to intubation or death HR:
HCQ: 1.04 (95 % CI 0.82-1.32)
AZT: 1.03 (95 % CI 0.81-1.31)
|
|
|
|
|
|
|
No HCQ: 274
AZT: 102 (37.2 %)
|
|
Rosenberg et al.[78]
|
Multicenter, retrospective, observational study, USA
|
HBP: 57
Diabetes: 7
Obesity: 43
|
ICU: 12.8
Mechanical ventilation: 9.5
|
NR
|
500 OD. Unknown duration
|
|
In-hospital mortality aHR:
|
|
|
|
|
|
|
HCQ + AZT: 735 |
1.35 (95% CI 0.76-2.40) |
|
|
|
|
|
|
HCQ: 271 |
1.08 (95 % CI 0.63-1.85) |
|
|
|
|
|
|
AZT: 211 |
0.56 (95 % CI 0.26-1.21) |
|
|
|
|
|
|
SOC: 221 |
Reference |
Guerin et al.[79]
|
Retrospective, observational study, France
|
HBP: 12.8
Diabetes: 3.4
Obesity: 13.6
|
Outpatients
|
1 (41 %)
Within 15 (57.9)
|
500 day 1, 250 OD days 2-5
|
|
Time to clinical recovery, median (range):
|
|
|
|
|
|
|
HCQ + AZT: 20 |
7 (2-40) |
|
|
|
|
|
|
AZT: 34 |
7 (3-48) |
|
|
|
|
|
|
SOC: 34 |
27 (6-48) |
Barbosa et al.[80]
|
Open label, controlled non-randomized trial, Brazil
|
HBP: 26.5
Diabetes: 13.4
Obesity: 7.7
|
Outpatients
|
5.2 ± 3.1
|
500 OD 5 days
|
|
Need for hospitalization
|
|
|
|
|
|
|
HCQ+AZT: 412 |
1.9 % |
|
|
|
|
|
|
SOC: 224 |
5.4 % |